Non-small-cell lung carcinoma

Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Retrieved on: 
Thursday, April 25, 2019
Health, Pharmaceutical, General Health, Cancer treatments, Clinical medicine, Organic compounds, Lung cancer, RTT, Antineoplastic drugs, Breakthrough therapy, Bristol-Myers Squibb, Pembrolizumab, Non-small-cell lung carcinoma, Paclitaxel, Melanoma

KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Key Points: 
  • KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.
  • KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
  • Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.
  • When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA should be administered prior to chemotherapy when given on the same day.

BerGenBio to Present NSCLC and AML Clinical Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019

Retrieved on: 
Tuesday, April 23, 2019
Cancer treatments, Clinical medicine, Cancer, Antineoplastic drugs, Tyrosine kinase receptors, Protein kinase inhibitors, AXL receptor tyrosine kinase, Merck, Bemcentinib, Pembrolizumab, Non-small-cell lung carcinoma, Chemotherapy

The posters presented at ASCO will be made available on www.bergenbio.com in the Investors / Presentations section at time of presentation.

Key Points: 
  • The posters presented at ASCO will be made available on www.bergenbio.com in the Investors / Presentations section at time of presentation.
  • A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy.
  • First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML pts unfit for intensive chemotherapy: Phase II open-label study.
  • The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad Phase II oncology clinical development programme focussed on combination and single agent therapy in lung cancer and leukaemia.

BerGenBio to Present NSCLC and AML Clinical Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019

Retrieved on: 
Tuesday, April 23, 2019
Cancer treatments, Clinical medicine, Cancer, Antineoplastic drugs, Tyrosine kinase receptors, Protein kinase inhibitors, AXL receptor tyrosine kinase, Merck, Bemcentinib, Pembrolizumab, Non-small-cell lung carcinoma, Chemotherapy

The posters presented at ASCO will be made available on www.bergenbio.com in the Investors / Presentations section at time of presentation.

Key Points: 
  • The posters presented at ASCO will be made available on www.bergenbio.com in the Investors / Presentations section at time of presentation.
  • A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy.
  • First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML pts unfit for intensive chemotherapy: Phase II open-label study.
  • The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad Phase II oncology clinical development programme focussed on combination and single agent therapy in lung cancer and leukaemia.

Cantargia Phase I Clinical Results on the Antibody CAN04 Selected for Oral Presentation at ASCO

Retrieved on: 
Thursday, April 18, 2019
Cancer treatments, Clinical medicine, Drugs, RTT, Monoclonal antibodies, Merck, Lung cancer, Non-small-cell lung carcinoma, Pancreatic cancer, Cancer, Mapatumumab, Bemcentinib

The antibody CAN04 is investigated in a phase IIa clinical trial (CANFOUR) in patients with NSCLC or pancreatic cancer.

Key Points: 
  • The antibody CAN04 is investigated in a phase IIa clinical trial (CANFOUR) in patients with NSCLC or pancreatic cancer.
  • The data from phase I monotherapy in patients with NSCLC, pancreatic cancer or colorectal cancer has been selected as an oral presentation at the 2019 Annual ASCO meeting in the session Developmental Immunotherapy and Tumor Immunobiology.
  • "The selection of CAN04 phase I data as an oral presentation is a confirmation of the relevance CAN04 and the biological mechanisms addressed.
  • The main project, the antibody CAN04 (nidanilimab) is being studied in the clinical phase I/IIa CANFOUR with a primary focus on non-small cell lung cancer and pancreatic cancer.

Agilent Receives an Expanded FDA Approval for its Companion Diagnostic in NSCLC

Retrieved on: 
Wednesday, April 17, 2019
Technology, Software, Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, FDA, Cancer treatments, Clinical medicine, Medicine, Breakthrough therapy, Antineoplastic drugs, Merck, Pembrolizumab, Non-small-cell lung carcinoma, PD-L1, Immune system, Microsatellite instability, Checkpoint inhibitor

The FDA previously approved the assay to identify metastatic NSCLC patients whose tumors express PD-L1 Tumor Proportion Score (TPS) 50% for first-line treatment with KEYTRUDA.

Key Points: 
  • The FDA previously approved the assay to identify metastatic NSCLC patients whose tumors express PD-L1 Tumor Proportion Score (TPS) 50% for first-line treatment with KEYTRUDA.
  • This expanded indication enables pathologists to identify a larger population of previously untreated patients who are now eligible for treatment with KEYTRUDA.
  • By expanding the use of PD-L1 IHC 22C3 pharmDx, Agilent strives to continue our legacy of pioneering companion diagnostics to support the launch of landmark therapies.
  • Agilents PD-L1 IHC 22C3 pharmDx is the first and only companion diagnostic that has been clinically validated and approved to identify NSCLC patients eligible for KEYTRUDA.

OTITOPIC™ Pursues Additional New Indication for Dry Powder Inhalation of Aspirin as a Treatment for Non-Small-Cell Lung Cancer (NSCLC)

Retrieved on: 
Monday, April 8, 2019
Health, Oncology, Pharmaceutical, Other Health, Research, Other Science, Science, General Health, Lung cancer, Clinical medicine, Cancer, Neoplasms, Non-small-cell lung carcinoma, Aspirin, Treatment of lung cancer, Small-cell carcinoma, Lung, Tecemotide

OTITOPIC recently announced a new additional indication for treatment of lung cancer for its aspirin inhalation product.

Key Points: 
  • OTITOPIC recently announced a new additional indication for treatment of lung cancer for its aspirin inhalation product.
  • Delivering an inhaled Dry Powder formulation of Aspirin directly into the deep sites of the lung is a novel new approach to lung cancer treatment.
  • Small-cell lung cancer (15%20%) and non-small-cell lung cancer (NSCLC) (80%85%) are the main types of lung cancer.
  • Additionally, OTITOPIC is actively exploring new additional indication for treatment of lung cancer for its aspirin inhalation product, such as delivering inhaled dry powder formulation of Aspirin directly into the deep sites of the lung for treatment of lung cancer.

VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Retrieved on: 
Wednesday, April 3, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Chemical compounds, Organic compounds, Aromatic compounds, Quinazolines, Lung cancer, Chloroarenes, Amines, Gefitinib, Morpholines, Non-small-cell lung carcinoma, Epidermal growth factor receptor, Protein kinase inhibitor

A total of 452 patients were randomized 1:1 to VIZIMPRO 45 mg (n=227) or gefitinib 250 mg (n=225).

Key Points: 
  • A total of 452 patients were randomized 1:1 to VIZIMPRO 45 mg (n=227) or gefitinib 250 mg (n=225).
  • VIZIMPRO is approved in the EU for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.
  • A total of 452 patients were randomized 1:1 to VIZIMPRO 45 mg (n=227) or gefitinib 250 mg (n=225).
  • 4 Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients

Retrieved on: 
Tuesday, April 2, 2019
Health, Biotechnology, Clinical trials, Hospitals, Oncology, Pharmaceutical, Research, FDA, Science, Clinical medicine, Cancer, Bristol-Myers Squibb, Monoclonal antibodies, Breakthrough therapy, Lung cancer, Antineoplastic drugs, Nivolumab, Ipilimumab, Non-small-cell lung carcinoma, Small-cell carcinoma, Renal cell carcinoma

Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer and accounts for up to 85% of diagnoses.

Key Points: 
  • Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer and accounts for up to 85% of diagnoses.
  • OPDIVO (nivolumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
  • OPDIVO (nivolumab) is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
  • In MSI-H/dMMR mCRC patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg, immune-mediated pneumonitis occurred in 1.7% (2/119) of patients.

Data for Merck’s KEYTRUDA® (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR Annual Meeting 2019

Retrieved on: 
Monday, April 1, 2019
Health, Clinical trials, Oncology, Pharmaceutical, FDA, Clinical medicine, Cancer, Medicine, Lung cancer, Antineoplastic drugs, Cancer treatments, RTT, Breakthrough therapy, Non-small-cell lung carcinoma, Small-cell carcinoma, Pembrolizumab, Chemotherapy

Lung cancer, which forms in the tissues of the lungs, usually within cells lining the air passages, is the leading cause of cancer death worldwide.

Key Points: 
  • Lung cancer, which forms in the tissues of the lungs, usually within cells lining the air passages, is the leading cause of cancer death worldwide.
  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85 percent of all cases.
  • KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.
  • When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA should be administered prior to chemotherapy when given on the same day.

Resolution Liquid Biopsy Assay Outperforms Guardant360 in Retrospective Non-Small Cell Lung Carcinoma Comparison Pilot Study

Retrieved on: 
Monday, April 1, 2019
Technology, Data management, Hardware, Nanotechnology, Health, Biotechnology, Genetics, Oncology, General Health, Medicine, Clinical medicine, Biopsy, Lung cancer, Non-small-cell lung carcinoma, Liquid biopsy, Tyrosine kinase receptors

A cohort of 169 non-small cell lung cancer (NSCLC) patients with Guardant360 results were screened for gene fusions.

Key Points: 
  • A cohort of 169 non-small cell lung cancer (NSCLC) patients with Guardant360 results were screened for gene fusions.
  • The team found that the Resolution ctDx-Lung assay identified more actionable gene fusion mutations with higher allele frequencies than the Guardant360 test.
  • This study is another strong validation of our targeted NGS-based liquid biopsy platform and its ability to outperform other assays, such as the Guardant360 test, said Mark Li, CEO of Resolution Bioscience.
  • Resolution Bioscience, the Resolution Bioscience logo, and ctDx-Lung are trademarks of Resolution Bioscience, Inc. All other brands may be trademarks of their respective holders.